Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients

De Novo-Inclusion criteria 1. Males and females aged 6 years or over. 2. Recipients of cadaveric, living unrelated or living related kidney transplant, treated with CsA-Me, with or without corticosteroids, as primary immunosuppression. Maintenance-Inclusion criteria 1. Males and females aged 6 years or over. 2. Recipients of first or secondary cadaveric, living related or unrelated donor kidney transplant. 3. Patients currently receiving CsA-ME with or without Mycophenolate mofetil (MMF) or azathioprine, with or without corticosteroids as part of their immunosuppressive regimen for at least 3 months prior to Screening. 4. Patients in a stable condition in terms of graft function (serum creatinine not above 2.3 mg/dL (=204 µmol/L) at screening and at baseline, or not increased by more than 20% at baseline compared to values obtained at screening), no change of immune suppressive regimen due to graft malfunction, and any known clinically significant physical and/or laboratory changes for at least 2 months prior to enrollment. De Novo and Maintenance-Exclusion Criteria 1. Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ other than kidney. 2. Patients with any known hypersensitivity to MPA, EC-MPS or other components of the formulation (e.g. lactose). 3. Patients with thrombocytopenia (\< 75,000/mm3), with an absolute neutrophil count of \< 1,500/mm3, and/or leukocytopenia (\< 2,500/mm3), and/or hemoglobin \< 6 g/dL at Screening or Baseline. 4. Patients with a history of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin. Other protocol-defined inclusion/exclusion criteria may apply